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Simple Summary: Beyond its pre-eminent role in the context of tumor cell growth as well as
metastasis, the C-X-C motif chemokine receptor 4 (CXCR4) is a key player in the orchestration of
inflammatory responses to inflammatory stimuli. This review therefore particularly focuses on
summarizing the current knowledge on non-invasive imaging of tissue infiltration with CXCR4-
expressing immune cells in the context of diverse inflammatory conditions using positron emission
tomography. An overview of the current clinical and preclinical approaches in this context is provided,
and the recent advances in the development of dedicated, high-end CXCR4-targeted imaging tools
and theranostic agents are discussed.
Abstract: Given its pre-eminent role in the context of tumor cell growth as well as metastasis, the
C-X-C motif chemokine receptor 4 (CXCR4) has attracted a lot of interest in the field of nuclear
oncology, and clinical evidence on the high potential of CXCR4-targeted theranostics is constantly
accumulating. Additionally, since CXCR4 also represents a key player in the orchestration of in-
flammatory responses to inflammatory stimuli, based on its expression on a variety of pro- and
anti-inflammatory immune cells (e.g., macrophages and T-cells), CXCR4-targeted inflammation
imaging has recently gained considerable attention. Therefore, after briefly summarizing the current
clinical status quo of CXCR4-targeted theranostics in cancer, this review primarily focuses on imag-
ing of a broad spectrum of inflammatory diseases via the quantification of tissue infiltration with
CXCR4-expressing immune cells. An up-to-date overview of the ongoing preclinical and clinical
efforts to visualize inflammation and its resolution over time is provided, and the predictive value
of the CXCR4-associated imaging signal for disease outcome is discussed. Since the sensitivity and
specificity of CXCR4-targeted immune cell imaging greatly relies on the availability of suitable,
tailored imaging probes, recent developments in the field of CXCR4-targeted imaging agents for
various applications are also addressed.
Keywords: CXCR4; cancer; inflammation; molecular imaging; PET; SPECT; radioligand therapy
1. Introduction
Given its pre-eminent role in the context of tumor cell growth as well as metastasis,
the C-X-C motif chemokine receptor 4 (CXCR4) has attracted a lot of interest in nuclear
oncology. Powerful imaging agents and a theranostic concept targeting CXCR4 have
evolved during the last decade, and their increasing clinical impact is reflected by an eleven-
fold increase in the number of publications per year (PubMed search for “CXCR4 imaging
PET cancer”) during the last decade (2011–2020) and highlighted in several comprehensive
reviews [1–4].
Of note, CXCR4 is also endogenously expressed on various pro- and anti-inflammatory
immune cells, with particularly high expression levels on macrophages and T cells, making
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the receptor one of the key players in the orchestration of inflammatory responses of
the body to a variety of local and systemic inflammatory stimuli. Imaging inflammation
(i.e., infiltration of tissues by CXCR4-expressing immune cells) by targeting CXCR4 has
therefore become another very vibrant field of preclinical and clinical research. After a
short summary of the recent clinical advances in CXCR4-targeted imaging and radioligand
therapy (RLT) in cancer, this review will therefore particularly highlight the increasing body
of evidence of the clinically relevant role of CXCR4 imaging in the context of inflammatory
conditions. Important recent findings in preclinical studies in this field as well as the
very recent developments of innovative and promising new tracer concepts will also
be addressed.
2. CXCR4-Targeted Theranostics in Cancer and Its Limitations
2.1. CXCR4-Targeted PET Imaging
Although many underlying mechanisms and their implications for disease progression
are not elucidated yet, most tumors import a worsening prognosis with increasing CXCR4
expression, which is known to play an important role in both tumor cell proliferation and
metastasis [5]. Non-invasive imaging of receptor expression has become feasible through
the introduction of radiolabeled ligands that allow for whole-body SPECT or PET [2],
with the theranostic concept based on the cyclic pentapeptide tracers [68Ga]Pentixafor and
[177Lu]Pentixather being the farthest advanced into clinical practice.
Since CXCR4 expression is generally high among hematological malignancies, in-
cluding non-Hodgkin lymphoma (NHL), multiple myeloma (MM), chronic lymphocytic
leukemia (CLL) and acute myeloid leukemia (AML), most experience with CXCR4-directed
PET imaging is based on patients with these diseases [6].
In MM, CXCR4-targeted PET imaging using [68Ga]Pentixafor has been demonstrated
to yield complementary as well as superior results in both newly diagnosed as well as
advanced disease compared to [18F]FDG-PET [7–9]. Of note, marked inter- as well as
intra-individual differences of receptor expression as a sign of clonal heterogeneity [10] and
dynamic receptor regulation [11] have been observed, requiring further research to gain a
deeper understanding of the underlying biology. In AML, where the CXCR4/CXCL12 axis
is crucially involved in attraction of leukemic blasts into the protective bone marrow (BM)
niche, [68Ga]Pentixafor PET was able to identify CXCR4-positive patients in roughly 50%
of cases [12]. Another study revealed that the BM involvement of CLL is associated with
significantly higher tracer uptake as compared to healthy controls [13].
Additionally, CXCR4 has recently emerged as an interesting molecular target in
marginal zone lymphoma [14,15], gastric mucosa-associated lymphoid tissue (MALT)
lymphoma [16], mantle cell lymphoma [17], myeloproliferative neoplasms [18] as well
as primary lymphoma of the central nervous system [19]. In Waldenström macroglobu-
linemia/lymphoplasmacytic lymphoma, a disease in which about 40% of patients have
mutations in the CXCR4 gene, preliminary results with non-invasive PET imaging us-
ing [68Ga]Pentixafor have demonstrated promising results in both staging and therapy
response assessment. Of note, available data suggest potential superiority over [18F]FDG-
PET [20–22].
Beyond hematologic malignancies, CXCR4 overexpression has been described in
various solid cancers [23]. As in the case of the former, enhanced CXCR4 expression in solid
tumors characterizes more aggressive disease and portends an unfavorable prognosis [24].
This is also supported by a study that demonstrated an inverse correlation between tumor
differentiation and CXCR4 expression, as assessed by immunohistochemistry of surgical
samples in neuroendocrine neoplasms [25].
However, in contrast to the sometimes-pronounced CXCR4 expression observed in
ex vivo immunohistochemistry studies using tumor biopsies, the corresponding in vivo
[68Ga]Pentixafor PET/CT studies demonstrated a very heterogeneous, often modest, and
in some cases even absent CXCR4-mediated tracer uptake in solid cancers [26–29], limiting
the broad diagnostic application of this imaging approach. To date, only few solid tumor
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entities have shown pronounced overexpression of CXCR4, as assessed by PET/CT. For
example, some studies have reported intense overexpression of CXCR4 in patients with
SCLC [30–32], and Bluemel et al. demonstrated feasibility of CXCR4-directed PET/CT
imaging in patients with advanced adrenocortical cancer. In their initial patient cohort,
about 70% of subjects demonstrated sufficient tumoral [68Ga]Pentixafor uptake to qualify
for potential CXCR4-directed radioligand therapy (RLT) [33].
2.2. CXCR4-Targeted Radioligand Therapy
Pentixather, the therapeutic counterpart of Pentixafor, can be labeled with various
radionuclides for CXCR4-directed radioligand therapy (RLT) [34]. In patient-derived
xenograft mouse models of acute lymphocytic leukemia (ALL) and AML [35], a significant
eradication of leukemic blasts has been recorded. These encouraging results led to the
translation to the human setting, with three patients with refractory AML successfully
undergoing CXCR4-directed RLT.
To date, more than 70 chemokine receptor-directed radioligand therapies using
[177Lu/90Y]Pentixather have been conducted. Given the high specificity of the therapeutic
compound for human CXCR4, the therapy is generally safe and well-tolerated [36]. So far,
the largest studies have examined the use of RLT in advanced stage, heavily pretreated MM
patients. Although initial response rates were high, no substantial overall survival benefit
could be observed [37,38]. Another pilot investigation showed encouraging results using
[177Lu/90Y]Pentixather RLT in diffuse large B cell lymphoma [39]. Currently, one prospec-
tive trial for CXCR4-directed RLT, which will investigate the activity and tolerable dose
and side effects of [177Lu/90Y]Pentixather RLT in patients with MM or NHL (COLPRIT
trial, EudraCT 2015-001817-28), is in preparation.
Due to its effect on the BM, CXCR4-directed RLT usually requires subsequent HSC
transplantation. However, in hematologic diseases, profound myeloablation by CXCR4-
targeted RLT prior to autologous or allogeneic hematopoietic transplantation is a desired
effect that has already been enhanced by the addition of anti-cluster of differentiation 66
(CD66)-directed or anti-CD20-directed radioimmunotherapy in some cases [39].
In contrast, in solid malignancies, in which hematopoietic cell transplantation is
not an established and suitable approach, such myeloablation is certainly of concern.
[177Lu/90Y]Pentixather RLT without stem cell rescue might be technically feasible for
tumors with pronounced receptor overexpression, as exemplified by adrenocortical cancer
or SCLC, but further development and prospective investigations are definitely required.
3. Beyond Cancer: CXCR4-Targeted Imaging of Immune Cell Infiltrates
Since CXCR4 is also expressed on a variety of pro- and anti-inflammatory immune
cells, with a pronounced overexpression on macrophages and T cells, CXCR4-directed
molecular imaging provides the opportunity to gain insight into the highly sophisticated
and orchestrated role of chemokines and their receptors in inflammatory processes [4,40].
Of note, due to the relatively broad spectrum of immune cells expressing CXCR4, imaging
of inflammatory processes using CXCR4-targeted tracers such as [68Ga]Pentixafor will
invariably depict the global infiltration of inflamed tissue with pro- and anti-inflammatory
immune cells, without the possibility to specifically attribute the imaging signal to a specific
immune cell subtype (except by immunohistochemical analyses) [41].
3.1. Cardiovascular Diseases
Pilot studies investigating CXCR4-directed PET imaging in the setting of acute my-
ocardial infarction (AMI) demonstrated high [68Ga]Pentixafor uptake in the infarcted
myocardium [42,43], which correlated with the presence of pro-inflammatory cells in the
ischemic area [42]. Another investigation revealed an association between CXCR4 expres-
sion in the BM and the severity of the systemic inflammatory response, and suggested that
AMI patients with initially high myocardial tracer uptake developed less scar tissue in
the infarcted area and presented with a better functional outcome at follow-up [44]. How-
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ever, the latter findings are in contradiction with a recent pre-clinical study in post-AMI
mice that provided evidence that imaging-guided on-peak CXCR4 inhibition (three days
after AMI) lowered the risk of ventricular rupture, accelerated resolution of post-infarct
inflammation and improved the outcome (please also see Section 4) [45]. In line with this
finding, beneficial effects of CXCR4 blockade by attenuated inflammatory gene expression
via regulatory T cells (Tregs) have been reported [46]. CXCR4-positive cardio-protective
Tregs were found to accumulate in infarcted myocardium and mediastinal lymph nodes
in a mouse model, as well as in patients after AMI, interpreted as a sign of pro-healing
autoimmunity [47]. More research to deepen our understanding of the spatial and temporal
orchestration of CXCR4 expression of the various cell types involved in AMI and to explore
potential therapeutic interventions is highly warranted.
3.2. Inflammation Imaging
Recently, a study in 72 lymphoma patients found that [68Ga]Pentixafor PET/MRI
was suitable to visualize inflammation within human carotid plaques, with histological
evidence for co-localization of CXCR4 and CD68 [48], thereby confirming previous results
of chemokine receptor overexpression in macrophage-rich plaques in a rabbit model of
atherosclerosis [49]. In addition, two independent studies using [68Ga]Pentixafor PET/CT
demonstrated an association between cardiovascular risk factors and CXCR4 expression
within atherosclerotic plaques on a per-patient basis [50,51]. Derlin et al. investigated
CXCR4 expression in the coronary arteries of AMI patients after stent-based reperfusion
and observed the highest [68Ga]Pentixafor uptake in the culprit lesions, which the authors
ascribed to inflammatory changes and/or stent-induced injury [52]. In another study in
patients undergoing CXCR4-directed RLT for hematologic malignancy, Li et al. were able
to show an additional anti-inflammatory therapeutic effect on atherosclerotic plaques [53].
While most of the PET signal in [68Ga]Pentixafor PET is considered to originate from
macrophages, the variety of different cell types (T cells, B cells and/or progenitor cells)
expressing CXCR4 on their surface adds to the complexity of the underlying biology [54].
Furthermore, the CXCR4/CXCL12 axis seems to exert both athero-protective as well as
atherogenic, pro-inflammatory effects [55]. This could explain the results of a human carotid
plaque study that showed CXCR4 overexpression in both stable and unstable atherosclerotic
plaques, with the highest receptor expression on macrophages and macrophage-derived
foam cells [56]. In addition, in a recent retrospective comparison of oncologic patients
undergoing imaging with [68Ga]Pentixafor and [18F]FDG PET/CT for staging purposes,
imaging results obtained with both tracers showed only a weak correlation (r = 0.28;
p < 0.01). However, CXCR4-directed imaging was able to identify more lesions, and the
degree of plaque calcification was found to correlate negatively with [68Ga]Pentixafor
uptake [57]. While these preliminary results are interesting and hint towards a suitability
of [68Ga]Pentixafor PET for differentiating between vulnerable and stable plaques, future
research to further investigate CXCR4 biology in atherosclerosis and its clinical implications
is highly warranted.
Another highly relevant clinical application of CXCR4-targeted inflammation imaging
is the non-invasive assessment of disease activity in idiopathic pulmonary fibrosis (IPF) [58].
In a study with 28 subjects, high CXCR4 expression was primarily observed in macrophages,
lymphocytes and epithelial cells in areas of vast fibrotic remodeling. [68Ga]Pentixafor
PET/CT was found to sensitively detect early changes in pulmonary CXCR4 expression
upon treatment with an antifibrotic drug, with a decrease in [68Ga]Pentixafor uptake 6–12
weeks after treatment initiation as the only independent predictor of long-term outcome.
CXCR4 expression in IPF may thus serve as a valuable biomarker for individualized
antifibrotic therapies.
3.3. Infection Imaging
Non-invasive imaging of CXCR4 with [68Ga]Pentixafor PET/CT has also been in-
vestigated in infectious diseases. In a pilot study of 29 patients with suspected chronic
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osteomyelitis, Bouter et al. targeted the elevated CXCR4 expression on T cells to success-
fully visualize inflammatory activity, with superior diagnostic accuracy of [68Ga]Pentixafor
PET/CT for detection of chronic bone infections as compared to granulocyte-directed
99mTc-besilesomab and 99mTc-labeled white blood cells [59,60]. As another example, in
a pilot investigation of 13 patients with complicated urinary tract infections after kid-
ney transplantation, infectious foci could successfully be detected by imaging leukocyte
infiltration using [68Ga]Pentixafor PET/MRI [61].
Lastly, in the context of the recent COVID-19 pandemic, CXCR4-directed imaging of
both infectious sites and reactive systemic responses of the reticulo-endothelial system
has been initiated (Figure 1). In a first patient with acute COVID-19 symptoms, bilateral
pneumonia with reactive hilar and mediastinal lymph nodes as well as inflammatory foci
in the lymphoid tissue of the neck were clearly visualized by [68Ga]Pentixafor PET.
Furthermore, reactive activation of both bone marrow and spleen as a response of
the immune system to the viral infection was reflected by increased tracer uptake in
these organs. Although preliminary in nature, these data demonstrate the potential of
[68Ga]Pentixafor PET for imaging of local immune cell infiltration as a result of viral
infection, and further studies to corroborate these findings are underway.
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Figure 1. Maximum intensity projection of CXCR4-directed PET/CT with [68Ga]Pentixafor in a 67-
year-old patient with acute COVID-19 infection. Beyond bilateral pneumonia with reactive hilar and 
mediastinal lymph nodes, inflammatory foci in the lymphoid tissue of the neck could be depicted. 
Figure 1. i te sity projection of CXCR4-directed PET/CT with [68Ga]Pentixafor in a
67-year-old patient with acute COVID-19 infection. Beyond bilateral pneumonia with reactive hilar
and mediastinal lymph nodes, inflammatory foci in the lymphoid tissue of the neck could be depicted.
In addition, the reactive activation of both bone marrow and spleen is visualized. The patient’s
condition deteriorated quickly after imaging and he was transferred to the ICU on the day after
PET/CT [C. Lapa, unpublished data].
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4. Imaging of CXCR4-Positive Immune Cells in Preclinical Models
Interestingly, as opposed to the many examples of successful in vivo imaging of
CXCR4-positive immune cell infiltrates in various clinical scenarios of inflammation and
infection summarized above, preclinical studies in this context are rather rare. On the one
hand, this is certainly due to the limitations encountered by imaging probes targeted to the
murine CXCR4 receptor. As described in more detail in the next section, high mCXCR4
expression in mouse tissues such as liver, lung and spleen leads to considerable activity
accumulation in these organs, thus obscuring the oftentimes weak but significant signal
arising from immune cell infiltration of the heart, muscle or aortic plaques in mice. On the
other hand, [68Ga]Pentixafor, the only currently available tracer with negligible background
accumulation in mCXCR4-positive organs, is highly selective for hCXCR4. With a mCXCR4
affinity of >1 µM [62], [68Ga]Pentixafor can only provide a very weak mCXCR4-specific
signal, challenging its usefulness for investigating CXCR4-mediated pathological processes
in mouse models.
That this is nevertheless feasible in some instances, however, has been shown in sev-
eral preclinical studies investigating the dynamics and involvement of CXCR4 expression in
cardiac diseases [63–66]. In a mouse model of acute myocardial infarction, [68Ga]Pentixafor
PET allowed identification of an increased inflammatory leucocyte content in the injured
ventricle at 1 and 3 days after infarction. Additionally, a delayed resolution of myocardial
inflammation (no decreased [68Ga]Pentixafor uptake in the injured myocardium between
days 1 and 3 after infarction) was shown to be a negative prognostic marker for sur-
vival [45]. Work from the same group also demonstrated the utility of [68Ga]Pentixafor
PET for detecting diffuse myocardial inflammation in a mouse model of pressure overload
heart failure [63] and was able to reveal the tight inflammatory interaction between the
myocardium and the kidneys after acute myocardial inflammation [66]. In the latter study,
the gradual decline in [68Ga]Pentixafor uptake in injured myocardium and the kidneys
over time revealed identical kinetics of post-infarction resolution of inflammation.
In the context of atherosclerosis, CXCR4-targeted imaging of vulnerable plaques via
[68Ga]Pentixafor PET has already found its way into clinical application (see Section 3.2).
Its superiority for accurately differentiating plaque phenotypes compared to other tracers
has been very recently shown in an ex vivo autoradiography study using sections of human
carotid plaques [67]. In this study, tracers targeted to different molecular markers for plaque
imaging (sst2, leukocyte function-associated antigen-1 (LFA-1), folate receptor (FR) and
CXCR4) were comparatively evaluated. Here, differential CXCR4-mediated accumulation
of [67Ga]Pentixafor was shown to allow the most precise differentiation between early,
stable (calcified) and vulnerable plaques. Another very recent study used 64Cu-labeled
viral macrophage inflammatory protein, [64Cu]DOTA-vMIP-II (see entry 22, Table 1), for
imaging atherosclerosis in Apoe-/- mice. This study revealed that, in addition to the well-
documented accumulation of CXCR4-targeted probes in macrophages and foam cells in
atherosclerotic plaques [49], a large proportion of [64Cu]DOTA-vMIP-II accumulation in
atherosclerotic lesions was mediated by CXCR4-expressing plaque endothelial cells (ECs).
This, and the finding that plaque regression was accompanied by a loss of CXCR4 on aortic
endothelium, led to the conclusion that high CXCR4 expression on plaque ECs may serve
as a molecular marker for endothelial vulnerability/injury [68].
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Table 1. Summary of recently developed novel CXCR4-targeted imaging agents (2019–2021). If not stated otherwise in the table, all internalization and biodistribution data were obtained
at 1 h incubation or at 1 h p.i. respectively, and internalization studies were performed in the cell line used for tumor induction.
Entry Compound Affinity [IC50, nM]
Internalized [% of Total
Cellular Activity] Tumor Uptake [%iD/g] Liver [%iD/g] T/Muscle Ratio Ref.
1 [64Cu]CB-bicyclam
8 (hCXCR4) b n.d. SUVmax: 7.4 ± 1.8 (U87.CXCR4) 13.8 23.6 ± 2.7 [69]
2 (mCXCR4) a SUVmax: 0.8 ± 0.1 (U87) 3.0 ± 0.5
2 [18F]MCFB 111 ± 4 a ~40 3.3 ± 0.9 (U2932) 63 ± 5 4.0 ± 0.8 [70]1.8 ± 0.1 (SUDHL-8) 52 ± 3 2.1 ± 0.3
3 [99mTc]AMD3465 n.d. n.d. 2.1 ± 0.4 (MCF-7) 25 ± 7 4.7 [71]
4 [18F]RPS-534 218 ± 38 c ~7 (2 h) 7.2 ± 0.3 (PC3-CXCR4) 19.1 ± 0.4 42.4 ± 0.1 [72]
5 [76Br]HZ270-1 6.7 ± 0.7 c n.d. 9.5 ± 1.3 (U87.CXCR4, 24 h) 7.6 ± 1.3 (24 h) n.d. [73]
6 [18F]5 6.9 d n.d. 4.0 ± 0.3 (SCCHN, 1.5 h) 1.2 ± 0.1 (90 min) 25 [74]
7 [125I]CPCR4.3
5.4 ± 1.5 (hCXCR4) e 68 ± 3 (MCF-7) n.d. 21.2 ± 2.9 n.d. [75,76]4.9 ± 1.7 (mCXCR4) f
8 [177Lu]DOTA-r-a-ABA-CPCR4
1.5 ± 0.1 (hCXCR4) e 65 ± 6 (Chem1) 18.3 ± 3.7 (Daudi) 11.9 ± 1.6 413 ± 100
[62]182 ± 26 (mCXCR4)
f
9 [177Lu]DOTA-r-a-ABA-iodoCPCR4
1.7 ± 0.6 (hCXCR4) e 91 ± 4 (Chem1) 17.2 ± 2.0 (Daudi) 27.1 ± 1.9 226 ± 3649 ± 1 (mCXCR4) f
10 [125I]MK007 10.2 ± 4.0 e n.d. 1.1 ± 0.1 (Jurkat) 35.3 ± 1.0 ~2 [77]
11 [99mTc]PentixaSPECT 10.2 ± 2.4 g 95 (Chem1) 8.6 ± 1.3 (Jurkat) 7.7 ± 0.7 29 ± 6 [78]
12 [99mTc]HYNIC-L Kd 3.3 ± 0.4 (DU-4475) ~9 3.2 ± 0.9 (DU-4475) 2.0 ± 0.4 n.d. [79]13 [177Lu]DOTA-HYNIC-L Kd 3.2 ± 0.4 (DU-4475) ~9 4.2 ± 1.1 (DU-4475) 2.3 ± 0.5 n.d.
14 [68Ga]5 15.6 ± 4.2 e 91 (Chem1) 7.9 ± 1.4 (Daudi) 0.36 ± 0.01 115 ± 48 [80]
15 [67Ga]FRM001 2.3 ± 0.5 a ~15 12.0 ± 2.0 (CCRF-CEM, 4 h) 16.1 ± 2.7 (4h) 112 [81]
16 [68Ga]BL-01 21.2 ± 16 a n.d. 10.2 ± 2.6 (Daudi) 7.1 ± 1.3 23 ± 4 [82]17 [177Lu]BL-01 7.1 ± 1.7 a n.d. 14.0 ± 1.1 (Daudi) 10.3 ± 0.9 32 ± 3
18 [18F]BL-08 11.6 ± 7.0 a n.d. 7.6 ± 1.4 (Daudi) 0.62 ± 0.02 108 ± 25 [83]19 [18F]BL-09 13.4 ± 2.3 a n.d. 6.6 ± 2.1 (Daudi) 0.56 ± 0.09 83 ± 19
20 [64Cu]NOTA-CP01 1.6 ± 1.0 h n.d. SUVmax: 1.3 ± 0.2 (EC109, 6 h) SUVmax: ~3.5 (6 h) 15.4 ± 3.0 (6 h) [84]
21 [99mTc]T140 analog 1.9 a negligible 0.5 ± 0.1 (U87.CXCR4, 2 h) 22.7 ± 5.0 (2 h) ~2 (2 h) [85]
22 [64Cu]DOTA-vMIP-II n.d. n.d. ~4.5 (aortic plaque) n.d. ~3 [68]
23 [64Cu]MCo-CVX-6D 0.07 ± 0.02 (FRET) n.d. 5.7 ± 0.5 (U87.CXCR4, 24 h) 23.3 ± 2.1 (24 h) 19.9 ± 4.7 [86]
24 [64Cu]Ubiquitin n.d. n.d. 1.6 ± 0.6 (4T1, 2 h) ~4.8 (2 h) 8.5 ± 2.3 (2 h) [87]
a competitive binding assay using [125I]SDF-α as radioligand; b calcium flux assay; c competitive binding assay using [61Ga]pentixafor as radioligand; d fluorescence-based competitive binding assay against
TN14003; e competitive binding assay using [125I]FC-131 as radioligand; f competitive binding assay using [125I]CPCR4.3 as radioligand; g competitive binding of [99mTc]PentixaSPECT vs cold FC-131;
h competitive binding of [64Cu]NOTA-CP01 vs unlabeled precursor.
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Two other very recent preclinical studies using a small-molecule tracer (entry 6,
Table 1) and N-[11C]methyl-AMD3465 as PET imaging agents further highlight the rele-
vance of CXCR4 as a target for immune cell imaging [74,88]. In a model of carrageenan-
induced inflammation, significantly higher accumulation of the benzenesulfonamide ligand
[18F]5 was observed in the paw edema lesion as compared to the control paw, indicative
of the inflammation-induced infiltration with CXCR4-positive immune cells [74]. In the
context of immuno-oncology, an accurate assessment of tumor immune cell infiltration as
a response to immunomodulatory cancer treatments is of pivotal importance. That this
can be achieved by CXCR4-targeted immune cell imaging has been recently demonstrated
preclinically [88]. Tumors of xenograft-bearing mice were either treated with single-fraction
radiotherapy or single-fraction radiotherapy, followed by immunization with a single dose
of a virus-based antitumor vaccine. Radiation therapy alone already led to a 3.5-fold
increase of N-[11C]methyl-AMD3465 uptake in the treated tumor compared to untreated
controls, and this effect was further enhanced by immunization. This therapy-induced
tumor infiltration with CXCR4-expressing immune cells was efficiently inhibited by daily
administration of AMD3100 on the days following irradiation.
Although probably only visualizing the tip of the iceberg concerning the multitude of
potentially relevant applications, these examples impressively demonstrate the potential of
CXCR4-directed imaging of immune cells and their trafficking to sites of inflammation, and
an increasing number of preclinical and clinical studies in this context can be anticipated
for the coming years.
5. CXCR4-Targeted Imaging Agents: An Ever-Evolving Field
Based on the identification of the first highly potent, synthetic CXCR4-targeted anti-
HIV antagonists in the late 1990s [89,90], and fueled by the recognition of the important
role of CXCR4 in cancer growth, progression and metastasis in the early 2000s [91], the
development of CXCR4-targeted imaging agents has been a field of highly active research
since the mid-2000s (Figure 2). Several excellent reviews on the progressive advances
in the design of CXCR4-directed nuclear, fluorescent and hybrid imaging agents have
been published over the years [1,3,92–94]. Since they already provide an impressive
and comprehensive overview of the historical evolution of the different tracer concepts
(summarized in Figure 2), only very recent (2019 and later) advances and developments
will be discussed in this review.
As evident from the summary in Figure 2, the relevance of tracers based on the
T140-peptide scaffold has been decreasing during the last decade, primarily based on
inherent physicochemical characteristics of the peptide backbone (highly cationic nature).
Due to inevitably high non-specific background accumulation in the excretion organs,
in particular in the liver, T140-based ligands such as [68Ga]NOTA-NFB imaging deliver
up to ten times higher effective doses in patients compared to [68Ga]Pentixafor [95,96],
challenging their potential for further clinical application. Thus, not surprisingly, only
one novel T140—based compound (for SPECT imaging) has been published since 2019
(entry 21, Table 1), displaying the same characteristics as previous probes based on this
scaffold [85].
In contrast, the development of optimized mono- and bi-cyclam-based tracers (entries
1–5, Table 1) for PET and SPECT imaging is still ongoing. As summarized in Table 1,
reasonable to high tumor/background ratios and CXCR4-specificity of tumor uptake were
found for several novel ligands. Unfortunately, however, their overall pharmacokinet-
ics are generally vitiated by extensive activity accumulation in the excretion organs. A
large proportion of the pronounced hepatic uptake of radiolabeled (mono/bi)cyclams
in mice, however, has been shown to be blockable by co-injection of the corresponding
unlabeled competitor [69,71,72], a finding that is in line with the documented expression
of mCXCR4 in mouse liver [69,97,98] and thus indicative of a significant contribution of
CXCR4-specific tracer accumulation. This effect has also been investigated in more detail
during the evaluation of the cross-bridged bi-cyclam [64Cu]CB-bi-cyclam (entry 1, Table 1,
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and Figure 3). Here, hepatic [64Cu]CB-bi-cyclam uptake was successfully blocked by pre-
dosing with 5 mg/kg of Cu-CB-bi-cyclam (IC50 = 8 nM) or Cu2-CB-bi-cyclam (IC50 = 3 nM),
whereas the low-affinity “standard” competitors AMD3100 (IC50 = 204 nM) and AMD3465
(IC50 = 114 nM) were not able to competitively displace the radioligand in vivo [69]. As
opposed to the first-generation, non-stabilized AMD-based tracer [64Cu]AMD 3100, for
which extensive hepatic tracer accumulation was not only observed in mice [99], but also
in humans [100], an effect that is due to excessive transchelation of 64Cu in the liver and
general metabolic instability of the complex, [64Cu]CB-bi-cyclam shows excellent in vivo
stability. Thus, for this analog, only minimal tracer accumulation in the human liver may
be anticipated, strongly supporting its suitability for clinical translation.
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As found during the in vivo evaluation of the ono-cyclam analog [18F]MCFB (entry 2,
Table 1), organic cation tra sporters (OCT1, OCT2 and OCT3) also seem to be partly in-
volved in the uptake of the cationic radiolabeled mono/bi-cyclams into the liver. When an
excess of th OCT-substrate metformin was co-administered with [18F]MCFB, reduction
of tracer ccumulation in th liver by approximately 25% was observed, with a less pro-
nounced effect in the kidneys [70]. Another interesting effect that was observed during the
evaluation of different radio-iodinated and radio-brominated mono-cyclam a alogs [73] is
the d pendence of their general pharmacokinetics and targ ting ffici ncy on the radio-
labeling site. Of the two radio-brominated is mers i vestigated, [76Br]HZ270-1 (entry 5,
Table 1, 2-[76Br]bromo-analog) showed distinctly low r background accumulation in all
organs, a d a doubled tumor accumul tion compared to the corresponding 3-[76Br]bromo-
analog, highlighting the importance of establishing detailed structur activity relat onships
in tracer development.
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As exemplified by the sheer number of novel analogs published since 2019 (entries
7–20, Table 1), small cyclic peptides (5 to 8 amino acids) play a prominent role as scaffolds
for novel CXCR4-targeted imaging agents [62,75–84].
Based on the clinical success of [68Ga]Pentixafor/[177Lu]Pentixather as a first CXCR4-
targeted theranostic pair, several novel analogs based on the same pentapeptide back-
bones have been developed (entries 7–13, Table 1; Figure 3). Here, the major innova-
tion lies in the design of an alternative linker structure between the peptide core and
the radiolabel/fluorescent dye. Compared to the parent peptides [68Ga]Pentixafor and
[177Lu]Pentixather, the compounds bearing the novel r-a-ABA-linker (entries 8 and 9,
Table 1) or variants thereof (entries 10 and 11, Table 1) show particularly high hCXCR4
affinities (improvement by a factor of 2–10 compared to [68Ga]Pentixafor) and enhanced
internalization, indicative of an increasingly agonistic profile [62]. Of note, the use of
the iodo-Tyr3-containing Pentixather-backbone decreases the selectivity of the ligands for
the human CXCR4 receptor (entries 8 and 9, Table 1), providing tracers with decreased
species selectivity and thus potential applicability for studying CXCR4-related pathologies
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in murine models. As observed for the cyclam-based tracers (entries 1–5, Table 1, and
discussed in detail above), this increase in affinity to murine CXCR4 is consistently accom-
panied by an increasing tracer uptake in mCXCR4-expressing tissues such as lung, liver,
spleen and bone marrow. Thus, in analogy to, e.g., [64Cu]CB-bi-cyclam (entry 1, Table 1), the
high but blockable hepatic activity level observed for [177Lu]DOTA-r-a-ABA-iodoCPCR4
is mCXCR4-specific and not the result of an unfavorable pharmacokinetic profile with
hepatobiliary clearance of the ligand. The same applies to [99mTc]PentixaSPECT (entry 11,
Table 1), for which relatively high hepatic uptake was observed in mice, but not in patients
(see Figure 4), further corroborating the relevance of mCXCR4-mediated tracer uptake in
mouse liver and the danger of misinterpreting it as “unfavorable tracer pharmacokinetics”.
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head (C) (3 h p.i.) [78].
In contrast, [125I]CPCR4.3 (entry 7, Table 1; Figure 3), with a log P = 0.51, truly shows
predominant clearance via the liver and intestines, in addition to mCXCR4-driven liver
uptake, and thus is not suited for in vivo imaging purposes [75]. However, due to its
excellent affinity to both human and mouse CXCR4, it may serve as an excellent preclinical
tool for the sensitive detection of low levels of CXCR4 expression in vivo, e.g., via ex vivo
autoradiography [76].
Another highly promising approach is the use of the cyclic peptide Ac-Arg-Ala-[D-
Cys-Arg-2-Nal-His-Pen]-COOH [101] as a scaffold for tracer development. The corre-
sponding [68Ga]NOTA-AMBS-Ahx-conjugated analog (entry 14, Table 1; Figure 3) shows
excellent CXCR4-targeting in vitro and in vivo, and despite lower absolute uptake in
Daudi xenografts (ca. 50% of the uptake found for [68Ga]Pentixafor [102]), improved
tumor/background ratios due to particularly low background accumulation [80].
Intense efforts have also been directed towards the development and optimization of
imaging probes/theranostic pairs based on the LY2510924 cyclic octapeptide sequence (en-
tries 15–20, Table 1; Figures 2 and 3). Pioneered by the development of [67Ga]FRM001 [81],
a series of closely related ligands for CXCR4-targeted theranostics (entries 16 and 17,
Table 1) and PET imaging (entries 18–20, Table 1) were designed and progressively opti-
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mized [82,83]. Of note, in a direct comparative biodistribution study, tracer accumulation
in Daudi xenografts and in kidneys was identical for [18F]BL-08 and [68Ga]Pentixafor at 1
and 2 h p.i. However, due to substantially lower background accumulation of [18F]BL-08
in all other organs, tumor/background ratios and imaging contrast were superior for
the radio-fluorinated LY2510924 analog [83]. In contrast, [64Cu]NOTA-CP01, in which
only a very short linker between the peptide core and the radiolabel was used, shows
less-promising results [84].
Furthermore, three highly interesting and diverse protein-based approaches have
been pursued (entries 22–24, Table 1 [68,86,87]), all of which showed some promise for
imaging of CXCR4 expression in vivo, albeit with the common limitations associated with
using macromolecules for imaging applications (slow clearance kinetics, high non-specific
background accumulation).
Overall, it can be anticipated that in the “race for clinical application”, the novel
peptide-based tracers with their highly optimized pharmacokinetics and excellent CXCR4-
targeting properties will certainly start from the pole position, closely followed by cyclam-
based candidates such as [64Cu]CB-bi-cyclam. The increasing insight into CXCR4 receptor–
ligand interactions and expanding structure–activity relationships will certainly also sup-
port the development of improved ligands for more complex applications, such as hybrid
(radiolabeled/fluorescent) tracers for intraoperative guidance [103].
6. Conclusions
Based on its eminent role in both tumor biology as well as in inflammation, CXCR4
is a molecular imaging target of utmost interest and with high potential as a predictive
marker for disease outcome in the context of the aforementioned pathologies.
Especially in inflammation imaging, the current first “proof-of-concept” data in pa-
tients need to be further validated in prospective clinical trials. However, the existing data
clearly show the high potential of this approach for specifically visualizing inflammation
and its resolution over time in a broad spectrum of inflammatory diseases. CXCR4-targeted
imaging may thus serve as a tool for non-invasive therapy control after anti-inflammatory
treatments and for providing personalized anti-inflammatory treatments to improve dis-
ease outcome. Additionally, CXCR4-directed imaging of immune cells holds great promise
to address some other urgent clinical questions, such as the need for an imaging tool to
quantify the influx of CXCR4-positive immune cells into immunologically “cold” tumors
after checkpoint inhibition therapy. First preclinical data hint towards a general feasibility
of such an approach [88]. This, however, needs careful in-depth validation, also including
a careful selection of cancer patients who might profit from such an approach (e.g., cancers
with negligible tumoral CXCR4 expression).
With the continuous emergence of additional, improved radiopharmaceuticals, a
further expansion of the scope of CXCR4-targeted imaging and therapy can be anticipated.
This does not only encompass an expansion of the preclinical and clinical scope towards
other CXCR4-driven inflammatory pathologies, but also a broadening of the spectrum of
applicable imaging modalities, now including SPECT, optical imaging (e.g., endoscopy) or
a combination of both (hybrid surgical guidance).
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